Eosinophilic esophagitis (EoE) is a chronic inflammatory disease driven by immune mechanisms, characterized by abnormal eosinophilic infiltration of the esophageal epithelium. EoE′s pathogenesis is closely associated with food allergens, and clinical manifestations primarily include dysphagia, food impaction, and children patients may also have growth restriction. The European Society for Paediatric Gastroenterology, Hepatology, and Nutrition first published guidelines for the management of pediatric EoE in 2014. With increasing understanding of the disease mechanisms and treatment responses, the 2024 guidelines have comprehensively updated the diagnostic and therapeutic strategies.This paper provides a systematic interpretation of the 2024 guidelines, focusing on the revised diagnostic criteria, optimization of dietary therapy, and improved management strategies for esophageal strictures. Furthermore, a comparison of the 2014 and 2024 guidelines highlights significant advancements in EoE management over the past decade and their implications for clinical practice.

This article provides an interpretation of the EULAR/PReS recommendations for the diaganosis and management of Still′s disease focusing on the diagnostic criteria, therapeutic targets, and strategies for managing complications in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still′s disease (AOSD). The guidelines introduce, for the first time, the unified nomenclature of "Still′s disease" for both sJIA and AOSD, emphasizing the importance of early recognition and stepwise management. Particular attention is given to the role of IL-1 and IL-6 inhibitors in reducing glucocorticoid use. This article aims to assist clinicians in China in better understanding and applying these guidelines to enhance the diagnosis and treatment of Still′s disease.

Objective To develop a continuous care program for patients with cardiac implantable electronic devices(CIED)utilizing the Omaha system,and to assess its effectiveness.This study aims to provide a reference for the continuous care of patients with CIED.Methods Using the Omaha system as the theoretical framework,based on literature search and semi-structured interviews,a continuity of care program for CIED patients based on the Omaha system was constructed through 2 rounds of expert inquiry.Convenience sampling method was used to select CIED implant patients from the cardiovascular department of a tertiary hospital in Wuhan as the research subjects.61 patients admitted from April to June 2024 were assigned as an experimental group with a continuity of care program based on the Omaha system;61 patients admitted from December 2023 to March 2024 were designated as a control group and received routine nursing measures.The Omaha performance indicators and quality of life at 3 months after discharge were compared between 2 groups upon admission and 1 month after discharge.Results The final 2 groups each included 59 patients.A month after discharge,the Omaha efficacy index in the experimental group was higher than that in the control group,and 3 months after discharge,the quality of life in the experimental group was higher than that in the control group(P＜0.001).Conclusion The CIED patient continuity of care program based on the Omaha system could improve patients'cognitive level,promote healthy behavior,enhance their self-efficacy,and improve their quality of life.

Objective To develop a continuous care program for patients with cardiac implantable electronic devices(CIED)utilizing the Omaha system,and to assess its effectiveness.This study aims to provide a reference for the continuous care of patients with CIED.Methods Using the Omaha system as the theoretical framework,based on literature search and semi-structured interviews,a continuity of care program for CIED patients based on the Omaha system was constructed through 2 rounds of expert inquiry.Convenience sampling method was used to select CIED implant patients from the cardiovascular department of a tertiary hospital in Wuhan as the research subjects.61 patients admitted from April to June 2024 were assigned as an experimental group with a continuity of care program based on the Omaha system;61 patients admitted from December 2023 to March 2024 were designated as a control group and received routine nursing measures.The Omaha performance indicators and quality of life at 3 months after discharge were compared between 2 groups upon admission and 1 month after discharge.Results The final 2 groups each included 59 patients.A month after discharge,the Omaha efficacy index in the experimental group was higher than that in the control group,and 3 months after discharge,the quality of life in the experimental group was higher than that in the control group(P＜0.001).Conclusion The CIED patient continuity of care program based on the Omaha system could improve patients'cognitive level,promote healthy behavior,enhance their self-efficacy,and improve their quality of life.

This article provides an interpretation of the EULAR/PReS recommendations for the diaganosis and management of Still′s disease focusing on the diagnostic criteria, therapeutic targets, and strategies for managing complications in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still′s disease (AOSD). The guidelines introduce, for the first time, the unified nomenclature of "Still′s disease" for both sJIA and AOSD, emphasizing the importance of early recognition and stepwise management. Particular attention is given to the role of IL-1 and IL-6 inhibitors in reducing glucocorticoid use. This article aims to assist clinicians in China in better understanding and applying these guidelines to enhance the diagnosis and treatment of Still′s disease.

Eosinophilic esophagitis (EoE) is a chronic inflammatory disease driven by immune mechanisms, characterized by abnormal eosinophilic infiltration of the esophageal epithelium. EoE′s pathogenesis is closely associated with food allergens, and clinical manifestations primarily include dysphagia, food impaction, and children patients may also have growth restriction. The European Society for Paediatric Gastroenterology, Hepatology, and Nutrition first published guidelines for the management of pediatric EoE in 2014. With increasing understanding of the disease mechanisms and treatment responses, the 2024 guidelines have comprehensively updated the diagnostic and therapeutic strategies.This paper provides a systematic interpretation of the 2024 guidelines, focusing on the revised diagnostic criteria, optimization of dietary therapy, and improved management strategies for esophageal strictures. Furthermore, a comparison of the 2014 and 2024 guidelines highlights significant advancements in EoE management over the past decade and their implications for clinical practice.

To interpret the clinical practice guidelines for pediatric and eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis (non-EoE EGID), jointly developed by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. The guidelines provide new standards for the diagnosis and treatment of non-EoE EGID. They include detailed explanations on disease classification, diagnostic and therapeutic challenges, guideline development methodology, epidemiology, etiological mechanisms, symptoms, endoscopic and imaging examinations, other tests, differential diagnosis, and treatment strategies. The paper explores the importance of comprehensive assessment in children with non-EoE EGID. Improvement suggestions are proposed, such as developing symptom assessment tools, conducting quality of life impact studies, standardizing eosinophil density reporting, refining diagnostic criteria, and formulating specific treatment guidelines. These measures aim to enhance the diagnostic and therapeutic accuracy for non-EoE EGID and improve the clinical management of affected children.

To interpret the clinical practice guidelines for pediatric and eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis(non-EoE EGID),jointly developed by the European Society for Paediatric Gastroenterology,Hepatology and Nutrition and the North American Society for Pediatric Gastroenterology,Hepatology and Nutrition.The guidelines provide new standards for the diagnosis and treatment of non-EoE EGID.They include detailed explanations on disease classification,diagnostic and therapeutic challenges,guideline development methodology,epidemiology,etiological mechanisms,symptoms,endoscopic and imaging examinations,other tests,differential diagnosis,and treatment strategies.The paper explores the importance of comprehensive assessment in children with non-EoE EGID.Improvement suggestions are proposed,such as developing symptom assessment tools,conducting quality of life impact studies,standardizing eosinophil density reporting,refining diagnostic criteria,and formulating specific treatment guidelines.These measures aim to enhance the diagnostic and therapeutic accuracy for non-EoE EGID and improve the clinical management of affected children.

Currently, there is a lack of localized guidelines or consensus on the management of Ebstein anomaly (EA) in China, particularly concerning the treatment of neonates and infants. The 2024 Expert Consensus issued by the American Association for Thoracic Surgery provides detailed guidance on the clinical management of EA, covering key aspects such as the timing of surgical interventions, selection of surgical techniques, and postoperative management. The interpretation of this consensus is of great significance for thoracic surgeons in China to understand the latest international academic developments and can serve as a valuable reference for clinical practice. The consensus outlines the latest surgical techniques adopted internationally, including the Starnes procedure, biventricular repair, and 1.5 ventricle repair, and provides an in-depth analysis of the optimal timing and strategies for interventions in different cases. This offers a theoretical foundation and technical reference for advancing the field in China, contributing to the standardization and regulation of EA treatment.

In 2022，the International Society for Pediatric and Adolescent Diabetes（ISPAD）set up an international expert group from many disciplines to jointly formulate a consensus guide for clinical practice of ISPAD in 2022 for children and adolescents（under 18 years old）with diabetic ketoacidosis and hyperglycemic hyperosmolar state.The purpose of this paper was to interpret the ISPAD guidelines，so as to provide the new clinical reference for diagnosis and management of diabetic ketoacidosis and heperglycemic hyperosmolar state in children and adolescents in China.